Effect of Pharmacological and Neurostimulation Interventions for Cognitive Domains in Patients with Bipolar Disorder: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

References

• Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18(5):440–450. doi:10.1111/bdi.1242327566286
   PubMed Web of Science ®Google Scholar
• Bora E, Hidiroglu C, Ozerdem A, et al. Executive dysfunction and cognitive subgroups in a large sample of euthymic patients with bipolar disorder. Eur Neuropsychopharmacol. 2016;26(8):1338–1347. doi:10.1016/j.euroneuro.2016.04.00227139077
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006;8(2):103–116. doi:10.1111/j.1399-5618.2006.00277.x16542180
   PubMed Web of Science ®Google Scholar
• Atre-Vaidya N, Taylor MA, Seidenberg M, Reed R, Perrine A, Glick-Oberwise F. Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry Neuropsychol Behav Neurol. 1998;11(3):120–126.9742510
   PubMedGoogle Scholar
• Duarte W, Becerra R, Cruise K. The relationship between neurocognitive functioning and occupational functioning in bipolar disorder: a literature review. Eur j Psychol. 2016;12(4):659–678. doi:10.5964/ejop.v12i4.90927872673
   PubMedGoogle Scholar
• Cipriani G, Danti S, Carlesi C, Cammisuli DM, Di Fiorino M. Bipolar disorder and cognitive dysfunction: a complex link. J Nerv Ment Dis. 2017;205(10):743–756. doi:10.1097/NMD.000000000000072028961594
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Carvalho AF, Vieta E, Kessing LV. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. Eur Neuropsychopharmacol. 2016;26(10):1541–1561. doi:10.1016/j.euroneuro.2016.08.01127593623
   PubMed Web of Science ®Google Scholar
• Paterson A, Parker G. Lithium and cognition in those with bipolar disorder. Int Clin Psychopharmacol. 2017;32(2):57–62. doi:10.1097/YIC.000000000000015227741027
   PubMed Web of Science ®Google Scholar
• Dias VV, Balanzá-Martinez V, Soeiro-de-souza MG, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand. 2012;126(5):315–331. doi:10.1111/j.1600-0447.2012.01910.x22881296
   PubMed Web of Science ®Google Scholar
• Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 2007;68(8):1186–1194. doi:10.4088/JCP.v68n080417854242
   PubMed Web of Science ®Google Scholar
• Yatham LN, Torres IJ, Malhi GS, et al. The international society for bipolar disorders-battery for assessment of neurocognition (ISBD-BANC). Bipolar Disord. 2010;12(4):351–363. doi:10.1111/j.1399-5618.2010.00830.x20636632
   PubMed Web of Science ®Google Scholar
• Van Rheenen TE, Lewandowski KE, Bauer IE, et al. Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: an overview of evidence. Bipolar Disord. 2020;22(1):13–27. doi:10.1111/bdi.1282131408230
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93(1–3):105–115. doi:10.1016/j.jad.2006.02.01616677713
   PubMed Web of Science ®Google Scholar
• Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149–162. doi:10.1111/acps.1213323617548
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Burdick KE, Martinez-Aran A, et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar Disord. 2018;20(3):184–194. doi:10.1111/bdi.1259529345040
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). 2019.
   Google Scholar
• Vrabie M, Marinescu V, Talaşman A, Tăutu O, Drima E, Micluţia I. Cognitive impairment in manic bipolar patients: important, understated, significant aspects. Ann Gen Psychiatry. 2015;14:41. doi:10.1186/s12991-015-0080-026609314
   PubMed Web of Science ®Google Scholar
• Păunescu R, Micluţia I. Outcome of cognitive performances in bipolar euthymic patients after a depressive episode: a longitudinal naturalistic study. Ann Gen Psychiatry. 2015;14:32. doi:10.1186/s12991-015-0070-226464576
   PubMed Web of Science ®Google Scholar
• White IR. Network meta-analysis. Stata J. 2015;15(4):951–985. doi:10.1177/1536867X1501500403
   Web of Science ®Google Scholar
• Rucker G, Schwarzer G. Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments. Res Synth Methods. 2017;8(4):526–536. doi:10.1002/jrsm.127028982216
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Dodd S, Bush AI, et al. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med. 2017;47(5):866–876. doi:10.1017/S003329171600293227894373
   PubMed Web of Science ®Google Scholar
• Baandrup L, Fagerlund B, Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):163–171. doi:10.1007/s00406-016-0711-827400927
   PubMed Web of Science ®Google Scholar
• Alda M, McKinnon M, Blagdon R, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatr. 2017;210(1):54–60. doi:10.1192/bjp.bp.115.173930
   Web of Science ®Google Scholar
• Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry. 2012;73(1):103–112. doi:10.4088/JCP.11m0729922152405
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lee Y, Rodrigues NB, et al. Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: a pilot study. J Affect Disord. 2021;293:73–77. doi:10.1016/j.jad.2021.05.07534174474
   PubMed Web of Science ®Google Scholar
• Ciappolino V, DelVecchio G, Prunas C, et al. The effect of DHA supplementation on cognition in patients with bipolar disorder: an exploratory randomized control trial. Nutrients. 2020;12(3):708. doi:10.3390/nu12030708
   PubMed Web of Science ®Google Scholar
• Fotso Soh J, Almadani A, Beaulieu S, et al. The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: a secondary analysis of a randomized controlled trial. J Affect Disord. 2020;262:149–154. doi:10.1016/j.jad.2019.11.01331733459
   PubMed Web of Science ®Google Scholar
• Pereira BDS, Tortella G, Lafer B, et al. The bipolar depression electrical treatment trial (better): design, rationale, and objectives of a randomized, sham-controlled trial and data from the pilot study phase. Neural Plast. 2015;2015:1–10. doi:10.1155/2015/684025
   Web of Science ®Google Scholar
• Lazowski LK, Townsend B, Hawken ER, Jokic R, Du Toit R, Milev R. Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial. BMC Psychiatr. 2014;14:202. doi:10.1186/1471-244X-14-202
   Web of Science ®Google Scholar
• Lu RB, Wang TY, Lee SY, et al. Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients. J Affect Disord. 2021;279:229–238. doi:10.1016/j.jad.2020.10.00333069121
   PubMed Web of Science ®Google Scholar
• Yang LL, Zhao D, Kong LL, et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) improves neurocognitive function in bipolar disorder. J Affect Disord. 2019;246:851–856. doi:10.1016/j.jad.2018.12.10230795490
   PubMed Web of Science ®Google Scholar
• Yatham LN, Mackala S, Basivireddy J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatr. 2017;4(3):208–217. doi:10.1016/S2215-0366(17)30046-9
   PubMed Web of Science ®Google Scholar
• Dean OM, Bush AI, Copolov DL, et al. Effects of N‐acetyl cysteine on cognitive function in bipolar disorder. Psychiatry Clin Neurosci. 2012;66(6):514–517. doi:10.1111/j.1440-1819.2012.02392.x23066769
   PubMed Web of Science ®Google Scholar
• Bersani FS, Minichino A, Bernabei L, et al. Prefronto-cerebellar tDCS enhances neurocognition in euthymic bipolar patients. Findings from a placebo-controlled neuropsychological and psychophysiological investigation. J Affect Disord. 2017;209:262–269. doi:10.1016/j.jad.2016.11.03727951511
   PubMed Web of Science ®Google Scholar
• Rakofsky JJ, Dunlop BW, Beyer JL, et al. Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. J Clin Psychopharmacol. 2014;34(3):383–385. doi:10.1097/JCP.000000000000007824717252
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry. 2014;75(12):1347–1355. doi:10.4088/JCP.13m0883925099079
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry. 2013;74(11):1076–1083. doi:10.4088/JCP.13m0841324330893
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012;14(7):697–706. doi:10.1111/bdi.1200623107220
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Gilmer WS, Dunn RT, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol. 2009;29(3):291–295. doi:10.1097/JCP.0b013e3181a497d719440086
   PubMed Web of Science ®Google Scholar
• Daglas R, Cotton SM, Allott K, et al. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: a 12-month follow-up study. Eur Psychiatr. 2016;31:20‐28. doi:10.1016/j.eurpsy.2015.09.460
   Web of Science ®Google Scholar
• Kocsis JH, Shaw ED, Stokes PE, et al. Neuropsychologic effects of lithium discontinuation. J Clin Psychopharmacol. 1993;13(4):268–275. doi:10.1097/00004714-199308000-000078376614
   PubMed Web of Science ®Google Scholar
• Shaw ED, Stokes PE, Mann JJ, Manevitz AZ. Effects of lithium carbonate on the memory and motor speed of bipolar outpatients. J Abnorm Psychol. 1987;96(1):64–69. doi:10.1037/0021-843X.96.1.643104434
   PubMed Web of Science ®Google Scholar
• Toniolo R, Fernandes F, Silva M, Dias R, Lafer B. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression. Nutr Neurosci. 2018;21:S6.
   Google Scholar
• Myczkowski ML, Fernandes A, Moreno M, et al. Cognitive outcomes of TMS treatment in bipolar depression: safety data from a randomized controlled trial. J Affect Disord. 2018;235:20–26. doi:10.1016/j.jad.2018.04.02229631203
   PubMed Web of Science ®Google Scholar
• Hu SH, Lai JB, Xu DR, et al. Efficacy of repetitive transcranial magnetic stimulation with quetiapine in treating bipolar II depression: a randomized, double-blinded, control study. Sci Rep. 2016;6:30537. doi:10.1038/srep3053727460201
   PubMed Web of Science ®Google Scholar
• Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29(8):1538–1545. doi:10.1038/sj.npp.130047115127079
   PubMed Web of Science ®Google Scholar
• Kauer-Sant’Anna M, Frey BN, Fijtman A, et al. Adjunctive tianeptine treatment for bipolar disorder: a 24-week randomized, placebo-controlled, maintenance trial. J Psychopharmacol. 2019;33(4):502–510. doi:10.1177/026988111982660230835152
   PubMed Web of Science ®Google Scholar
• Mansur RB, Subramaniapillai M, Lee Y, et al. Effects of infliximab on brain neurochemistry of adults with bipolar depression. J Affect Disord. 2021;281:61–66. doi:10.1016/j.jad.2020.11.12833296798
   PubMed Web of Science ®Google Scholar
• Perlis RH, Baker RW, Zarate CA, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatr. 2006;67(11):1747–1753.
   PubMed Web of Science ®Google Scholar
• Shi L, Schuh LM, Trzepacz PT, Huang LX, Namjoshi MA, Tohen M. Improvement of positive and negative syndrome scale cognitive score associated with olanzapine treatment of acute mania. Curr Med Res Opin. 2004;20(9):1371–1376. doi:10.1185/03007990412500449315383185
   PubMed Web of Science ®Google Scholar
• Schrauwen E, Ghaemi SN. Galantamine treatment of cognitive impairment in bipolar disorder: four cases. Bipolar Disord. 2006;8(2):196–199. doi:10.1111/j.1399-5618.2006.00311.x16542191
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2008;165(1):82–89. doi:10.1176/appi.ajp.2007.0705072417986678
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1093–1105. doi:10.1016/j.pnpbp.2007.09.01117959291
   PubMed Web of Science ®Google Scholar
• Jain S, Shukla SD, Sharma K, Bhatnagar M. Neuroprotective effects of Withania somnifera Dunn. in hippocampal sub-regions of female albino rat. Phytother Res. 2001;15(6):544–548. doi:10.1002/ptr.80211536389
   PubMed Web of Science ®Google Scholar
• Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol. 2005;144(7):961–971. doi:10.1038/sj.bjp.070612215711595
   PubMed Web of Science ®Google Scholar
• Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol. 2010;24(4):573–594. doi:10.1016/j.bpa.2010.10.00521619868
   PubMedGoogle Scholar
• Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130(Pt 10):2577–2588. doi:10.1093/brain/awm20317728357
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12(2):206–220. doi:10.1038/sj.mp.400190717033631
   PubMed Web of Science ®Google Scholar
• Kim TD, Hong G, Kim J, Yoon S. Cognitive enhancement in neurological and psychiatric disorders using transcranial magnetic stimulation (TMS): a review of modalities, potential mechanisms and future implications. Exp Neurobiol. 2019;28(1):1–16. doi:10.5607/en.2019.28.1.130853820
   PubMed Web of Science ®Google Scholar
• Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169–178. doi:10.1016/S1474-4422(04)00681-714980532
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147–152. doi:10.2174/15672050778036213717430239
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–458. doi:10.1016/j.neurobiolaging.2005.03.01615964100
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323–331. doi:10.3233/JAD-2008-1330918430999
   PubMed Web of Science ®Google Scholar
• Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatr Neurosci. 2011;36(2):78–86. doi:10.1503/jpn.100057
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361–368. doi:10.1016/j.biopsych.2008.03.00418436195
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468–475. doi:10.1016/j.biopsych.2008.04.02218534556
   PubMed Web of Science ®Google Scholar
• Holmay MJ, Terpstra M, Coles LD, et al. N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol. 2013;36(4):103–106. doi:10.1097/WNF.0b013e31829ae71323860343
   PubMed Web of Science ®Google Scholar
• Vieta E. The influence of medications on neurocognition in bipolar disorder. Acta Psychiatr Scand. 2009;120(6):414–415. doi:10.1111/j.1600-0447.2009.01503.x19906078
   PubMed Web of Science ®Google Scholar
• Xu N, Huggon B, Saunders KEA. Cognitive impairment in patients with bipolar disorder: impact of pharmacological treatment. CNS Drugs. 2020;34(1):29–46. doi:10.1007/s40263-019-00688-231808104
   PubMed Web of Science ®Google Scholar